The continuing pandemic response by the biotech industry has been ground-breaking, requiring collaborative, innovative thinking and partnering for the development of several SARS-CoV-2 vaccines, regulatory approvals, manufacturing, and entire supply chain delivery of desperately needed protection in less than one year. Truly historic!
The Government of Canada introduced the national biomanufacturing strategy to expand the production capacity of critical medicines to prevent and treat diseases such as COVID-19.
This webinar is focused on the importance of biomanufacturing in Canada. The keynote session and the panel discussion addresses why we need to ensure access to critical vaccines, other life-saving therapeutics and prevent locally developed biologics from moving outside of Canada for manufacturing and commercialization, impacting talent and economic growth.
In building biomanufacturing infrastructure, the symposium will examine the challenges companies face due to global competition for resources and how they overcome the challenge of speed and cost of building in the current environment.
The fee includes access to:
- Keynote speaker Mark Lievonen will provide an overview on Canada’s response to COVID-19 including procuring vaccines for Canadians, biomanufacturing challenges and opportunities, pandemic preparedness for the future
- Case study – Construction of the Biomanufacturing Centre (BMC) in Montreal
- Panel of companies currently building biomanufacturing infrastructure in Canada discussing challenges, opportunities and solutions
- Door Prizes